MTOR and COVID-19: In contrast, in KT recipients with symptomatic COVID-19, suspension of ADs or mTOR inhibitors was adopted in up to 79% of patients, especially in those patients requiring invasive ventilation, while CNI withdrawal (31.87%) was reserved in those who were severely symptomatic.